中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2015年
8期
1174-1178
,共5页
微RNAs/药理学%纳米复合物/治疗应用%前列腺肿瘤/药物疗法%肿瘤转移/药物疗法%骨肿瘤/继发性/药物疗法
微RNAs/藥理學%納米複閤物/治療應用%前列腺腫瘤/藥物療法%腫瘤轉移/藥物療法%骨腫瘤/繼髮性/藥物療法
미RNAs/약이학%납미복합물/치료응용%전렬선종류/약물요법%종류전이/약물요법%골종류/계발성/약물요법
MicroRNAs/PD%Nanocomposites/TU%Prostatic neoplasms/DT%Neoplasm metastasis/DT%Bone neoplasms/SC/DT
目的 通过构建可携带具有抗前列腺癌增殖作用的基因miR-15-a和miR-16-1的适体-去端胶原(APT-ATE),探讨载体系统的转染效率及其对前列腺癌细胞的抑制作用.方法 运用流式细胞仪,得出APT-ATE基因载体结构;利用粒径电位仪对APT-ATE/miRNA(适体-去端胶原/微小RNA)纳米复合物进行表征;利用基因转染考察APT-ATE/miRNA复合物在前列腺癌细胞(PC3和LNCaP)上的表达效果;CCK-8增殖抑制实验,考察APT-ATE/miRNA对前列腺癌细胞的抑制效果.结果 利用结构鉴定证明APT-ATE合成成功.定性定量转染效率实验证明APT修饰后的ATE对LNCaP细胞转染效率显著增加,证明APT的靶向作用.CCK-8细胞增殖实验证明,APT-ATE/miRNA可抑制前列腺癌细胞.裸鼠体内靶向性实验证明,APT-ATE/miRNA具有较好的骨靶向作用.结论 APT-ATE/miRNA有望成为今后靶向治疗骨转移性前列腺癌的基因药物.
目的 通過構建可攜帶具有抗前列腺癌增殖作用的基因miR-15-a和miR-16-1的適體-去耑膠原(APT-ATE),探討載體繫統的轉染效率及其對前列腺癌細胞的抑製作用.方法 運用流式細胞儀,得齣APT-ATE基因載體結構;利用粒徑電位儀對APT-ATE/miRNA(適體-去耑膠原/微小RNA)納米複閤物進行錶徵;利用基因轉染攷察APT-ATE/miRNA複閤物在前列腺癌細胞(PC3和LNCaP)上的錶達效果;CCK-8增殖抑製實驗,攷察APT-ATE/miRNA對前列腺癌細胞的抑製效果.結果 利用結構鑒定證明APT-ATE閤成成功.定性定量轉染效率實驗證明APT脩飾後的ATE對LNCaP細胞轉染效率顯著增加,證明APT的靶嚮作用.CCK-8細胞增殖實驗證明,APT-ATE/miRNA可抑製前列腺癌細胞.裸鼠體內靶嚮性實驗證明,APT-ATE/miRNA具有較好的骨靶嚮作用.結論 APT-ATE/miRNA有望成為今後靶嚮治療骨轉移性前列腺癌的基因藥物.
목적 통과구건가휴대구유항전렬선암증식작용적기인miR-15-a화miR-16-1적괄체-거단효원(APT-ATE),탐토재체계통적전염효솔급기대전렬선암세포적억제작용.방법 운용류식세포의,득출APT-ATE기인재체결구;이용립경전위의대APT-ATE/miRNA(괄체-거단효원/미소RNA)납미복합물진행표정;이용기인전염고찰APT-ATE/miRNA복합물재전렬선암세포(PC3화LNCaP)상적표체효과;CCK-8증식억제실험,고찰APT-ATE/miRNA대전렬선암세포적억제효과.결과 이용결구감정증명APT-ATE합성성공.정성정량전염효솔실험증명APT수식후적ATE대LNCaP세포전염효솔현저증가,증명APT적파향작용.CCK-8세포증식실험증명,APT-ATE/miRNA가억제전렬선암세포.라서체내파향성실험증명,APT-ATE/miRNA구유교호적골파향작용.결론 APT-ATE/miRNA유망성위금후파향치료골전이성전렬선암적기인약물.
Objective To construct a new gene delivery system based on atelocollagen (ATE),and explore that modified aptamer (APT),and APT-ATE/miRNA (miRNA-15a and miRNA-16-1) were successfully synthesized to treat bone-metastatic prostatic cancers.Methods Flow cytometry (FCM) analysis was used to characterize APT-ATE complex.The diameter and zeta potential of complexes were measured by Zetasizer Nano-ZS9.The prostatic cancer (PCa) distribution experiments were used to explore its biological characteristics and targeting ability of PCa cells (PC3 and LNCaP).The inhibition of APT-ATE complex on LNCaP cell was determined with the cholecystokinin (CCK)-8 assay.Results FCM results demonstrated the successful synthesis of ATE-APT complex.The cellular uptake of vectors was concentration-dependent.The gene expression in vitro indicated that the modification of APT could increase the efficiency of gene expression and PCa targeting ability of ATE vectors to LNCaP [prostate specific membrane antigen (PSMA) over-expressing prostate cancer cells].The result of biodistribution showed that the bone uptake of APT-ATE was higher than ATE-APT.Conclusions APT-ATE/miRNA might be useful for preclinical and clinical studies on the treatment of bone-metastatic PCa.